[go: up one dir, main page]

MA47043A1 - Composés indole carboxamides utiles comme inhibiteurs de kinase - Google Patents

Composés indole carboxamides utiles comme inhibiteurs de kinase

Info

Publication number
MA47043A1
MA47043A1 MA47043A MA47043A MA47043A1 MA 47043 A1 MA47043 A1 MA 47043A1 MA 47043 A MA47043 A MA 47043A MA 47043 A MA47043 A MA 47043A MA 47043 A1 MA47043 A1 MA 47043A1
Authority
MA
Morocco
Prior art keywords
compounds
kinase inhibitors
compounds useful
carboxamide compounds
indole carboxamide
Prior art date
Application number
MA47043A
Other languages
English (en)
Other versions
MA47043B1 (fr
Inventor
Qingjie Liu
Saleem Ahmad
Joseph A Tino
John E Macor
Andrew J Tebben
Hua Gong
Douglas G Batt
Khehyong Ngu
Scott Hunter Watterson
Weiwei Guo
Bertrand Myra Beaudoin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA47043A1 publication Critical patent/MA47043A1/fr
Publication of MA47043B1 publication Critical patent/MA47043B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de formule (i), ou un sel de ces composés, x représentant cr4 ou n, et r1, r2, r3, r4 et a étant tels que définis dans la description. L'invention concerne également des procédés d'utilisation de ces composés comme inhibiteurs de la tyrosine kinase de bruton (btk), ainsi que des compositions pharmaceutiques comprenant ces composés. Ces composés sont utiles dans le traitement, la prévention ou le ralentissement de la progression de maladies ou de troubles dans une diversité de domaines thérapeutiques, tels que les maladies auto-immunes et les maladies vasculaires.
MA47043A 2014-10-24 2015-10-23 Composés indole carboxamides utiles comme inhibiteurs de kinase MA47043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
PCT/US2015/057055 WO2016065226A1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Publications (2)

Publication Number Publication Date
MA47043A1 true MA47043A1 (fr) 2021-03-31
MA47043B1 MA47043B1 (fr) 2021-09-30

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
MA47043A MA47043B1 (fr) 2014-10-24 2015-10-23 Composés indole carboxamides utiles comme inhibiteurs de kinase
MA40301A MA40301B1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA40301A MA40301B1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Country Status (35)

Country Link
US (8) US9688629B2 (fr)
EP (2) EP3209656B1 (fr)
JP (1) JP6517928B2 (fr)
KR (2) KR102030305B1 (fr)
CN (2) CN110511209B (fr)
AR (2) AR102426A1 (fr)
AU (2) AU2015335694B2 (fr)
CA (1) CA2965517C (fr)
CL (1) CL2017000992A1 (fr)
CO (1) CO2017004481A2 (fr)
CY (2) CY1123401T1 (fr)
DK (2) DK3209656T3 (fr)
EA (2) EA032277B1 (fr)
ES (2) ES2809974T3 (fr)
HR (2) HRP20200819T1 (fr)
HU (2) HUE050592T2 (fr)
IL (2) IL251797B (fr)
LT (2) LT3461821T (fr)
MA (2) MA47043B1 (fr)
ME (2) ME03807B (fr)
MX (2) MX393057B (fr)
MY (2) MY188048A (fr)
PE (2) PE20170695A1 (fr)
PH (2) PH12017500725B1 (fr)
PL (2) PL3209656T3 (fr)
PT (2) PT3461821T (fr)
RS (2) RS60629B1 (fr)
SG (3) SG11201703188QA (fr)
SI (2) SI3209656T1 (fr)
SM (2) SMT202000412T1 (fr)
TN (2) TN2017000119A1 (fr)
TW (2) TWI743401B (fr)
UY (1) UY36371A (fr)
WO (1) WO2016065226A1 (fr)
ZA (1) ZA201804893B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
CN107108506B (zh) 2014-10-24 2022-06-21 武田药品工业株式会社 杂环化合物
HRP20192197T2 (hr) 2014-10-24 2020-11-13 Bristol-Myers Squibb Company Derivati karbazola
SG10201903621SA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
WO2017163078A1 (fr) 2016-03-24 2017-09-28 Mission Therapeutics Limited Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
PT3507282T (pt) * 2016-09-02 2020-12-23 Bristol Myers Squibb Co Processo para a preparação de compostos de indol carboxamida
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
EP3789040A4 (fr) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. Agent préventif et/ou thérapeutique pour maladie auto-immune comprenant un composé ayant une activité inhibitrice de btk en tant que principe actif
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115335039A (zh) * 2019-11-22 2022-11-11 加利福尼亚大学董事会 胱天蛋白酶6抑制剂和其用途
JP2023505155A (ja) * 2019-12-04 2023-02-08 アプティニックス インコーポレイテッド 神経変性疾患に関連する認知障害を治療する方法
EP4157446A1 (fr) * 2020-06-02 2023-04-05 GB002, Inc. Inhibiteurs de kinases
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL300432A (en) * 2020-08-07 2023-04-01 Shanghai Meiyue Biotech Dev Co Ltd An inhibitor of complement factor B, and the composition of the drugs, the method of preparation therefor and its use
WO2022035799A1 (fr) * 2020-08-10 2022-02-17 Prelude Therapeutics Incorporated Inhibiteurs de cdk à hétérocycle et leur utilisation
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022089620A1 (fr) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 Nouvelles formes cristallines de composé d'indole carboxamide et procédé de préparation associé
KR20230131251A (ko) * 2021-01-12 2023-09-12 쥐비005 인코포레이티드 키나아제 억제제로서의 인돌 유도체
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US20240383871A1 (en) 2021-08-30 2024-11-21 Bristol-Myers Squibb Company Compound useful for pet-imaging of bruton’s tyrosine kinase
WO2023227080A1 (fr) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 Composé protac, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (fr) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline-thromboxane-synthetase
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
WO2005005429A1 (fr) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
WO2005047290A2 (fr) 2003-11-11 2005-05-26 Cellular Genomics Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
EP1831227B1 (fr) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
EP1869052A1 (fr) 2005-04-06 2007-12-26 AstraZeneca AB Heterocycles substitues et leur utilisation en tant qu inhibiteurs de la chk1, de la pdk1 et de la pak
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
EP1896014A4 (fr) * 2005-06-30 2010-07-21 Glaxosmithkline Llc Composes chimiques
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1954290B1 (fr) 2005-11-22 2012-07-25 Merck Sharp & Dohme Corp. Composes tricycliques utilises comme inhibiteurs de kinases
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
CA2663178C (fr) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Derives de dibenzofurane comme inhibiteurs de pde-4 et pde-10
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
EP2125819B1 (fr) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires
US20100226917A1 (en) 2007-04-27 2010-09-09 Astrazeneca Ab Methods for the treatment of hematologic malignancies
WO2008144253A1 (fr) * 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
EP2151441A1 (fr) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Dérivés de béta-carboline en tant que substrats pour une enzyme
SG171815A1 (en) * 2008-12-19 2011-07-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
EP2789615B1 (fr) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles comme modulateurs de la kinase Btk et son utilisation
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
EP2582668B1 (fr) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Composes carboline carboxamide utiles en tant qu'inhibiteurs de kinase
EP2455378A1 (fr) 2010-11-03 2012-05-23 Philip Morris Products S.A. Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées
CA2817896A1 (fr) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibiteurs de la replication du vih
TW201247627A (en) 2011-04-28 2012-12-01 Bristol Myers Squibb Co Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
BR112013029620A2 (pt) 2011-05-17 2016-09-06 Hoffmann La Roche inibidores de tirosina quinase de bruton
ES2548414T3 (es) 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR20150048759A (ko) * 2012-09-07 2015-05-07 노파르티스 아게 인돌 카르복스아미드 유도체 및 그의 용도
BR112015031432A2 (pt) 2013-06-25 2017-07-25 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
HUE040645T2 (hu) * 2013-06-26 2019-03-28 Abbvie Inc BTK-inhibitor primer karboxamidok

Also Published As

Publication number Publication date
US10329274B2 (en) 2019-06-25
ES2809974T3 (es) 2021-03-08
US9802915B2 (en) 2017-10-31
US20190119245A1 (en) 2019-04-25
US9920031B2 (en) 2018-03-20
US10604504B2 (en) 2020-03-31
EP3209656A1 (fr) 2017-08-30
HUE050592T2 (hu) 2020-12-28
ES2795366T3 (es) 2020-11-23
IL251797B (en) 2020-07-30
TWI744218B (zh) 2021-11-01
KR20170061175A (ko) 2017-06-02
ME03740B (fr) 2021-01-20
US20160115126A1 (en) 2016-04-28
CO2017004481A2 (es) 2017-08-10
EP3461821A1 (fr) 2019-04-03
HRP20201146T1 (hr) 2020-10-30
CY1123395T1 (el) 2021-12-31
US20210107891A1 (en) 2021-04-15
DK3461821T3 (da) 2020-08-17
MX2017005259A (es) 2017-07-26
SMT202000412T1 (it) 2020-09-10
US20230192645A1 (en) 2023-06-22
CN107108583A (zh) 2017-08-29
HUE050706T2 (hu) 2020-12-28
US20190248760A1 (en) 2019-08-15
EP3209656B1 (fr) 2020-04-01
CN110511209B (zh) 2022-07-05
MA40301B1 (fr) 2019-12-31
AR120317A2 (es) 2022-02-09
PT3209656T (pt) 2020-06-08
BR112017007956A2 (pt) 2017-12-19
TW201630880A (zh) 2016-09-01
MA40301A1 (fr) 2019-03-29
IL251797A0 (en) 2017-06-29
TN2018000218A1 (en) 2019-10-04
LT3209656T (lt) 2020-07-27
AU2015335694B2 (en) 2020-04-02
TW201900612A (zh) 2019-01-01
ZA201804893B (en) 2020-07-29
MX393057B (es) 2025-03-24
WO2016065226A1 (fr) 2016-04-28
AU2019283921B2 (en) 2021-01-07
CN110511209A (zh) 2019-11-29
ME03807B (fr) 2021-04-20
CL2017000992A1 (es) 2017-11-17
US9688629B2 (en) 2017-06-27
DK3209656T3 (da) 2020-07-13
US11623921B2 (en) 2023-04-11
UY36371A (es) 2016-04-29
PT3461821T (pt) 2020-08-05
MY195561A (en) 2023-02-02
KR20180132167A (ko) 2018-12-11
MX2020008024A (es) 2022-06-10
IL262206A (en) 2018-11-29
AU2015335694A1 (en) 2017-06-08
AR102426A1 (es) 2017-03-01
SI3461821T1 (sl) 2020-09-30
MX377837B (es) 2025-03-11
PE20170695A1 (es) 2017-05-26
CN107108583B (zh) 2020-11-13
SG10201903578VA (en) 2019-05-30
PE20190710A1 (es) 2019-05-17
JP6517928B2 (ja) 2019-05-22
LT3461821T (lt) 2020-08-10
EA034931B1 (ru) 2020-04-08
EA201892207A1 (ru) 2019-02-28
IL262206B (en) 2020-07-30
SG11201703188QA (en) 2017-05-30
CA2965517C (fr) 2023-05-02
KR102001745B1 (ko) 2019-07-18
US20200165222A1 (en) 2020-05-28
WO2016065226A8 (fr) 2017-04-27
NZ731946A (en) 2021-02-26
KR102030305B1 (ko) 2019-10-08
JP2017531679A (ja) 2017-10-26
PH12020500265A1 (en) 2021-02-22
EP3461821B1 (fr) 2020-05-13
RS60312B1 (sr) 2020-07-31
CA2965517A1 (fr) 2016-04-28
SG10201903579SA (en) 2019-05-30
HRP20200819T1 (hr) 2020-08-07
SMT202000317T1 (it) 2020-07-08
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
MA47043B1 (fr) 2021-09-30
PL3461821T3 (pl) 2020-10-19
TWI743401B (zh) 2021-10-21
EA032277B1 (ru) 2019-05-31
US20170260160A1 (en) 2017-09-14
SI3209656T1 (sl) 2020-07-31
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
CY1123401T1 (el) 2021-12-31
TN2017000119A1 (en) 2018-07-04
EA201790740A1 (ru) 2017-08-31
MY188048A (en) 2021-11-12
RS60629B1 (sr) 2020-09-30
AU2019283921A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA41179A (fr) Composés inhibiteurs de parg
MA38648B1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
MA40290A1 (fr) Agents immunorégulateurs
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA44144B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43263B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45392B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52220B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
MA39506A1 (fr) Dérivés de 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phényl)-urée utilisés comme inhibiteurs de cxcr2